As reMYND alumnus and life-long supporter, Diverge is delighted to prepare the go-to-market of a next generation Alzheimer model, as such strengthening the offering of reMYND’s preclinical CRO in helping its clients to assess the in vivo pharmacology of their experimental neurodegenerative treatments.
reMYND’s CRO helps its clients assess in-vivo characteristics, pharmacokinetics/dynamics and the effects of their experimental treatments against Alzheimer’s disease in reMYND’s proprietary mouse models.
To strengthen its world-class service offering and leading expert signature, reMYND now seeks to expand into a so-called second-generation APP knock-in model, that is profoundly characterized yet exclusive in terms of availability for professional testing.
The joint project seeks to develop a strong and attractive positioning of the model within reMYND’s current portfolio of mouse models and read-outs, in the Alzheimer in-vivo proof-of-concept (PoC) market, and in line with what is envisaged by experts as the highest current standard of in-vivo PoC testing.
Hereto a series of in-depth interviews with a selection of key opinion leaders, leading funding agencies, pharma and biotech, complemented with an extensive market research effort, will be compiled into a launch plan.